Cover Image

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia

Show other versions (1)

<p>Members of the histone deacetylase (HDAC) family exhibit great promise as potential drug targets in pediatric tumors including neuroblastoma, medulloblastoma, ependymoma and Ewing’s sarcoma. HDAC inhibitors of various structural classes have shown anti-tumoral effects in pre-clinical pediat...

Full description

Saved in:
Bibliographic Details
Main Authors: Witt, Olaf (Author) , Milde, Till (Author) , Deubzer, Hedwig (Author) , Oehme, Ina (Author) , Kulozik, Andreas (Author) , Eisenmenger, Andreas (Author) , Abel, Ulrich (Author) , Karapanagiotou-Schenkel, Irini (Author)
Format: Article (Journal)
Language:English
Published: 2012
In: Klinische Pädiatrie
Year: 2012, Volume: 224, Issue: 06, Pages: 398-403
ISSN:1439-3824
DOI:10.1055/s-0032-1323692
Online Access:Verlag, Volltext: http://dx.doi.org/10.1055/s-0032-1323692
Verlag, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0032-1323692
Get full text
Author Notes:O. Witt, T. Milde, H.E. Deubzer, I. Oehme, R. Witt, A. Kulozik, A. Eisenmenger, U. Abel, I. Karapanagiotou-Schenkel
Description
Summary:<p>Members of the histone deacetylase (HDAC) family exhibit great promise as potential drug targets in pediatric tumors including neuroblastoma, medulloblastoma, ependymoma and Ewing’s sarcoma. HDAC inhibitors of various structural classes have shown anti-tumoral effects in pre-clinical pediatric tumor models as single agents or in combination treatments. Suberoylanilidehydroxamic acid (SAHA=vorinostat) is the most clinical advanced compound of the class and was approved by the US FDA in October 2006 for the treatment of refractory cutaneous T-cell lymphoma. In this phase I/II trial, pediatric patients with relapsed solid tumors, lymphoma or leukemias are treated according to an individualized dose escalation concept ensuring each individual patient to receive his optimal dose with respect to toxicity and efficacy. The study is accompanied by an extensive pharmacokinetic, pharmacodynamic and biomarker program.</p>
Item Description:Gesehen am 27.08.2018
Physical Description:Online Resource
ISSN:1439-3824
DOI:10.1055/s-0032-1323692

Similar Items